{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:37:16Z","timestamp":1769575036270,"version":"3.49.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00392-021-01964-2","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T07:02:52Z","timestamp":1636527772000},"page":"583-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Device-related risk of atrial fibrillation after closure of patent foramen ovale: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7094-5961","authenticated-orcid":false,"given":"Davor","family":"Vukadinovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Ukena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Ewen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Mahfoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"issue":"2","key":"1964_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00392-018-1334-z","volume":"108","author":"D Vukadinovi\u0107","year":"2019","unstructured":"Vukadinovi\u0107 D, Schirmer SH, Vukadinovic AN, Ukena C, Scheller B, Mahfoud F, B\u00f6hm M (2019) Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis. Clin Res Cardiol 108(2):157\u2013166. https:\/\/doi.org\/10.1007\/s00392-018-1334-z","journal-title":"Clin Res Cardiol"},{"issue":"20","key":"1964_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1212\/wnl.0000000000009443","volume":"94","author":"SR Mess\u00e9","year":"2020","unstructured":"Mess\u00e9 SR, Gronseth GS, Kent DM, Kizer JR, Homma S, Rosterman L, Carroll JD, Ishida K, Sangha N, Kasner SE (2020) Practice advisory update summary: Patent foramen ovale and secondary stroke prevention: Report of the Guideline Subcommittee of the American Academy of Neurology. Neurology 94(20):876\u2013885. https:\/\/doi.org\/10.1212\/wnl.0000000000009443","journal-title":"Neurology"},{"key":"1964_CR3","unstructured":"Corporation SJM (2016) Amplatzer PFO Occluder, Instructions for Use. St Jude Medical Corporation https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf12\/P120021c.pdf"},{"issue":"3","key":"1964_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/ccd.28527","volume":"95","author":"R Gevorgyan Fleming","year":"2020","unstructured":"Gevorgyan Fleming R, Kumar P, West B, Noureddin N, Rusheen J, Aboulhosn J, Tobis JM (2020) Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale. Catheter Cardiovascular Interv 95(3):365\u2013372. https:\/\/doi.org\/10.1002\/ccd.28527","journal-title":"Catheter Cardiovascular Interv"},{"issue":"43","key":"1964_CR5","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1093\/eurheartj\/eht283","volume":"34","author":"M Hornung","year":"2013","unstructured":"Hornung M, Bertog SC, Franke J, Id D, Taaffe M, Wunderlich N, Vaskelyte L, Hofmann I, Sievert H (2013) Long-term results of a randomized trial comparing three different devices for percutaneous closure of a patent foramen ovale. Eur Heart J 34(43):3362\u20133369. https:\/\/doi.org\/10.1093\/eurheartj\/eht283","journal-title":"Eur Heart J"},{"issue":"17","key":"1964_CR6","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.4244\/eij-d-18-00767","volume":"14","author":"AY Elgendy","year":"2019","unstructured":"Elgendy AY, Elgendy IY, Mojadidi MK, Mahmoud AN, Barry JS, Jneid H, Wayangankar SA, Tobis JM, Meier B (2019) New-onset atrial fibrillation following percutaneous patent foramen ovale closure: a systematic review and meta-analysis of randomised trials. EuroIntervention 14(17):1788\u20131790. https:\/\/doi.org\/10.4244\/eij-d-18-00767","journal-title":"EuroIntervention"},{"issue":"26","key":"1964_CR7","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1056\/NEJMoa1311376","volume":"370","author":"DJ Gladstone","year":"2014","unstructured":"Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O\u2019Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M (2014) Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 370(26):2467\u20132477. https:\/\/doi.org\/10.1056\/NEJMoa1311376","journal-title":"N Engl J Med"},{"issue":"26","key":"1964_CR8","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1056\/NEJMoa1313600","volume":"370","author":"T Sanna","year":"2014","unstructured":"Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370(26):2478\u20132486. https:\/\/doi.org\/10.1056\/NEJMoa1313600","journal-title":"N Engl J Med"},{"issue":"27","key":"1964_CR9","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/eurheartj\/ehaa495","volume":"41","author":"L Lauder","year":"2020","unstructured":"Lauder L, da Costa BR, Ewen S, Scholz SS, Wijns W, L\u00fcscher TF, Serruys PW, Edelman ER, Capodanno D, B\u00f6hm M, J\u00fcni P, Mahfoud F (2020) Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis. Eur Heart J 41(27):2556\u20132569. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa495","journal-title":"Eur Heart J"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01964-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-021-01964-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-021-01964-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T08:10:48Z","timestamp":1651219848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-021-01964-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1964"],"URL":"https:\/\/doi.org\/10.1007\/s00392-021-01964-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"D.V., B.S. and C.U. have nothing to disclose. S.E. received speaker's honorarium and\/or travel support from Medtronic, Recor, Bayer, Daiichi Sankyo, Novartis, AstraZeneca, Akcea Therapeutics and Pfizer. FM is supported by Deutsche Gesellschaft f\u00fcr Kardiologie (DGK), and Deutsche Forschungsgemeinschaft (SFB TRR219) and has received scientific support and speaker honoraria from Bayer, Boehringer Ingelheim, Medtronic and ReCor Medical. M.B. had no conflict in relation to this analysis and is supported by the Deutsche Forschungsgemeinschaft (SFB TRR 219).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}